Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
7.39
+0.12 (1.65%)
Sep 17, 2025, 4:00 PM EDT - Market closed
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Astria Therapeutics stock have a consensus rating of "Buy" and an average price target of $33, which forecasts a 346.55% increase in the stock price over the next year. The lowest target is $20 and the highest is $49.
Price Target: $33 (+346.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Astria Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $20 | Strong Buy | Maintains | $16 → $20 | +170.64% | Sep 17, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $49 | Buy | Reiterates | $49 | +563.06% | Sep 17, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $25 → $26 | Buy | Maintains | $25 → $26 | +251.83% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +116.51% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +116.51% | Jun 13, 2025 |
Financial Forecast
Revenue This Year
13.94M
Revenue Next Year
3.57M
from 13.94M
Decreased by -74.39%
EPS This Year
-2.17
from -1.68
EPS Next Year
-2.32
from -2.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 8.4M | |||
| Avg | 13.9M | 3.6M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | -39.7% | |||
| Avg | - | -74.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.94 | -1.73 | |||
| Avg | -2.17 | -2.32 | |||
| Low | -2.48 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.